论文部分内容阅读
我们采用治疗性乙肝疫苗（免疫复合物型和佐剂型）分别对１４５例各型乙型肝炎进行治疗，结果显示：乙肝主要指标ＡＬＴ复常率、ＨＢＶ－ＤＮＡ及ＨＢｅＡｇ阴转率，免疫复合物组分别为９２．９％、５０％和４１．９％；佐剂组分别为９４．１％、４２．８％和３５．２％，均明显高于对照组（Ｐ＜０．０１）。Ｔ细胞亚群中ＣＤ＋４／ＣＤ＋８细胞平均比值明显提高。试验表明：免疫复合物型疫苗和佐剂型疫苗对慢性肝炎，尤其是慢性活动性肝炎有较好疗效，而免疫复合物型优于佐剂型。本制剂无毒副作用，为生物制剂治疗乙型肝炎开辟了一条新途径
We used therapeutic hepatitis B vaccine (immunocomplex type and adjuvant type) for 145 cases of various types of hepatitis B were treated, the results showed that: the main indicators of hepatitis B ALT normalization rate, HBV-DNA and HBeAg negative conversion rate, immune complex group (92.9%, 50% and 41.9% respectively). The adjuvant groups were 94.1%, 42.8% and 35.2% respectively, which were significantly higher than those of the control group (P <0.01). The average ratio of CD + 4 / CD + 8 cells in T cell subsets was significantly increased. Experiments show that: immune complex vaccine and adjuvanted vaccine for chronic hepatitis, especially chronic active hepatitis have a better curative effect, and immunocomplex type is superior to the adjuvant type. The preparation has no toxic and side effects and opens up a new way for biological preparation to treat hepatitis B